📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-24 13:34
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
6 announcements match the current filters (relevance ≥ 5).
Aptus Pharma Plans ₹44.88 Cr Preferential Issue to Fund In-House Manufacturing & Capex
Aptus Pharma's Board has approved a proposal to raise ₹44.88 crore via a preferential issue of equity shares, subject to shareholder approval at the AGM on September 14, 2026. The company intends to allocate ₹25 crore towards capital expenditure to establish its own manufacturing facility, targeting ~20% in-house production to transition from a purely marketing-led model. The remaining proceeds include ₹10 crore for working capital and ₹9.88 crore for general corporate purposes and debt reduction over a 36-month period. Relative to its existing scale, the fundraise represents ~195% of net worth (₹23 crore) and ~63% of TTM revenue (₹71 crore).
Confidence: HIGH
What changedAptus Pharma proposed a ₹44.88 crore equity fundraise to transition towards backward-integrated in-house manufacturing and expand into Pan-India and export markets.
Why it mattersThe ₹25 crore capex program allows the company to gain quality and supply chain control by manufacturing ~20% of products in-house, significantly scaling its asset base relative to its current ₹23 crore net worth.
Total fundraise: ₹44.88 crCapex allocation: ₹25.00 crFundraise vs Net Worth: ~195%Fundraise vs TTM Revenue: ~63%Target in-house production: ~20%AGM date: September 14, 2026
📅 Short termFocus will remain on the outcome of the AGM on September 14, 2026, and receipt of statutory clearances for the preferential allotment.
📈 Long termIf executed successfully over the 36-month timeline, establishing internal manufacturing and entering international generic markets could sustainably improve operating margins and scale.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution from preferential allotment
- Execution and regulatory risks in setting up a greenfield pharma manufacturing facility
- Subject to shareholder and regulatory approvals
Key Highlights
Board approved ₹44.88 crore fundraise via preferential issue to identified investors
₹25 crore earmarked for capex including land, plant structure, storage, and vehicles
₹10 crore allocated to working capital and ₹9.88 crore to general corporate purposes/debt reduction
Company aims to produce ~20% of product requirements via in-house manufacturing
AGM for shareholder approval scheduled for September 14, 2026; deployment planned within 36 months
👀 What to Watch
Track shareholder approval at the AGM on September 14, 2026, along with regulatory clearances, issue pricing details, and subsequent land acquisition and construction milestones.
Aptus Pharma Seeks Shareholder Approval for ₹44.88 Cr Preferential Issue at ₹280/Share
Aptus Pharma Limited has issued a notice for its 16th Annual General Meeting scheduled on September 14, 2026, seeking shareholder approval for a preferential issue of ₹44.88 Cr. The company proposes to allot 16,02,870 equity shares of face value ₹10 at an issue price of ₹280 per share (including a ₹270 premium) for cash consideration. This capital raise represents approximately 63% of TTM revenue (₹71 Cr) and nearly double its current net worth (₹23 Cr), significantly boosting the company's balance sheet for future growth.
Confidence: HIGH
What changedAptus Pharma announced an AGM resolution seeking shareholder approval to raise ₹44.88 Cr via a preferential allotment of 16.03 lakh equity shares.
Why it mattersThe fundraise injects substantial equity capital equivalent to ~195% of the company's net worth (₹23 Cr), providing strong liquidity for business expansion and working capital.
Fundraise amount: ₹44,88,03,600Shares to be issued: 16,02,870 sharesIssue price per share: ₹280 (FV ₹10 + Premium ₹270)Fundraise vs Net worth: ~195%Fundraise vs TTM revenue: ~63%
📅 Short termMarket sentiment is likely to react positively to the sizable proposed equity capital infusion, though subject to shareholder approval at the AGM.
📈 Long termThe capital raise significantly strengthens the balance sheet, lowers financial leverage, and provides growth capital for scaling pharmaceutical operations.
⚠ Risk flags
- Equity dilution for existing non-participating shareholders
- Execution risk regarding effective deployment and return generation on the raised capital
Key Highlights
Proposed preferential issue of ₹44,88,03,600 (₹44.88 Cr) consisting of cash
Allotment of 16,02,870 equity shares of face value ₹10 at an issue price of ₹280 per share
Issue price includes a premium of ₹270 per equity share
AGM scheduled for September 14, 2026, with remote e-voting from September 11 to September 13, 2026
Allottees include public individuals, corporates, and select promoter group members
👀 What to Watch
Track shareholder voting results at the AGM on September 14, 2026, followed by regulatory in-principle listing approvals and subsequent capital deployment timelines.
Aptus Pharma Board Approves ₹44.88 Cr Preferential Equity Issue at ₹280/Share
Aptus Pharma Limited's Board has approved a preferential issue of up to 16,02,870 equity shares of face value ₹10 each at an issue price of ₹280 per share, aggregating to approximately ₹44.88 Crores. The issue is proposed to 190 allottees, and the relevant date for pricing was determined as August 14, 2026. The proposed fundraise is sizable relative to the company's financial profile, representing ~63% of TTM revenue (₹71 Cr) and ~195% of net worth (₹23 Cr). Shareholder approval will be sought at the 16th Annual General Meeting scheduled for September 14, 2026.
Confidence: HIGH
What changedThe Board approved the pricing and allotment structure for a ₹44.88 Cr preferential equity issue to 190 allottees.
Why it mattersThe fundraise injects fresh equity capital nearly double the company's current net worth of ₹23 Cr, significantly strengthening balance sheet liquidity, though it will result in equity dilution.
Total fundraise amount: Rs. 44.88 CroresNumber of shares proposed: 16,02,870Issue price per share: Rs. 280/-Fundraise vs Net Worth: ~195%Fundraise vs TTM Revenue: ~63%AGM Date: September 14, 2026
📅 Short termFocus shifts to shareholder voting at the September 14, 2026 AGM and subsequent allotment filings.
📈 Long termProvides substantial capital for balance sheet strengthening and business expansion; long-term ROE/ROCE will depend on the profitability of capital deployment.
⚠ Risk flags
- Equity dilution for existing shareholders
- Utilization/deployment execution risk given the size relative to existing operations
Key Highlights
Preferential issue of 16,02,870 equity shares approved at ₹280 per share (face value ₹10)
Total capital to be raised is approximately ₹44.88 Crores across 190 allottees
Fundraise represents ~195% of current Net Worth (₹23 Cr) and ~63% of TTM Revenue (₹71 Cr)
Valuation report taken on record with relevant date set as August 14, 2026
16th Annual General Meeting convened for Monday, September 14, 2026
👀 What to Watch
Track shareholder approval at the upcoming AGM on September 14, 2026, and monitor subsequent disclosures detailing the specific deployment and end-use of the ₹44.88 Cr proceeds.
16.10 Lakh Shares: Aptus Pharma to Consider Preferential Issue Price on August 17
Aptus Pharma has scheduled a board meeting for August 17, 2026, to determine the issue price for a preferential allotment of 16,10,100 equity shares. The relevant date for pricing calculation is set as August 14, 2026, in accordance with SEBI regulations. This fundraise follows a strong financial period where the company recorded TTM revenue of Rs 71 Cr and a healthy ROCE of 30%. The board will also finalize the notice for the 16th Annual General Meeting (AGM) to be held on September 14, 2026.
Confidence: HIGH
What changedThe company is initiating a formal process to raise capital through a preferential issue of 1.61 million shares, moving from internal planning to regulatory price determination.
Why it mattersFor a company with a net worth of Rs 23 Cr, a preferential issue of this size could significantly bolster the balance sheet for expansion, though it will lead to equity dilution for existing shareholders.
Shares to be issued: 16,10,100 unitsRelevant Date for pricing: August 14, 2026TTM Revenue: Rs 71 CrNet Worth: Rs 23 CrPromoter Holding: 72.89%
📅 Short termThe stock may see price volatility leading up to the August 17 board meeting as the market anticipates the issue price and potential allottees.
📈 Long termIf the capital is deployed toward high-margin pharmaceutical formulations or capacity expansion, it could sustain the company's 30% ROCE and drive revenue beyond the current Rs 71 Cr TTM level.
⚠ Risk flags
- Equity dilution for minority shareholders
- Specific use of proceeds not yet detailed
- Pricing risk relative to current market value
Key Highlights
Board meeting scheduled for August 17, 2026, to approve the valuation report and issue price.
Proposed issuance of 16,10,100 equity shares on a preferential basis.
Relevant date for determining the issue price is fixed as August 14, 2026.
16th Annual General Meeting (AGM) convened for September 14, 2026, via video conferencing.
Trading window for designated persons closed from August 12, 2026, until 48 hours post-meeting.
👀 What to Watch
Investors should monitor the outcome of the August 17 meeting to identify the issue price and the profile of the allottees (promoters vs. external investors). The utilization plan for the funds will be critical to assess future growth potential.
16.10 Lakh Shares: Aptus Pharma Approves Preferential Issue to 192 Investors
Aptus Pharma has approved a preferential issue of 16,10,100 equity shares to a broad group of 192 investors. The pricing will be determined based on a valuation report, with August 14, 2026, set as the 'Relevant Date' for minimum price calculation. This capital raise follows a strong FY26 performance where revenue grew 89% YoY to ‡46.57 Cr. Shareholders will vote on the proposal at the Annual General Meeting scheduled for September 14, 2026.
Confidence: HIGH
What changedThe company has transitioned from a board-level proposal to a formal plan for equity capital infusion via a preferential route.
Why it mattersFor a small-cap company with ‡71 Cr TTM revenue and high ROCE (30%), fresh capital is critical to sustain its recent high-growth trajectory and manage its ‡7 Cr debt.
Shares proposed to be issued: 16,10,100Number of allottees: 192Relevant Date for pricing: 2026-08-14AGM Date: 2026-09-14Estimated Dilution: ~8.6%
📅 Short termThe stock may see volatility leading up to the 'Relevant Date' as the market anticipates the floor price for the issuance.
📈 Long termIf the capital is used to expand the product portfolio or manufacturing capacity, it could support the company's transition into a larger pharmaceutical player.
⚠ Risk flags
- High number of allottees (192) is unusual for preferential issues and may lead to a fragmented cap table.
- Pricing risk if the valuation is set at a significant discount to the current market price.
Key Highlights
Issuance of 16,10,100 equity shares with a face value of ‡10 each.
Preferential allotment proposed to a total of 192 distinct investors.
Relevant Date for pricing fixed as August 14, 2026, 30 days prior to the AGM.
Annual General Meeting (AGM) to be held on September 14, 2026, for shareholder approval.
Estimated equity dilution of approximately 8.6% based on the current share capital.
👀 What to Watch
Investors should watch for the final issue price and the specific 'Object of the Issue' in the upcoming AGM notice to understand how the capital will be deployed for growth.
Aptus Pharma to consider fundraise via Preferential Allotment on August 8, 2026
Aptus Pharma has scheduled a board meeting for August 8, 2026, to evaluate a proposal for raising funds through a preferential allotment of equity shares or other securities. This move comes as the company shows strong growth, with TTM revenue reaching ₹71 Cr and a high ROCE of 30.0%. With a current net worth of ₹23 Cr and a manageable debt-to-equity ratio of 0.31, the fresh capital could be used for expansion or working capital. Investors should watch for the quantum of the fundraise and the identity of the allottees to gauge the impact on equity dilution.
Confidence: HIGH
What changedThe company is initiating a formal process to raise fresh capital through a preferential issue, moving beyond its current internal accruals.
Why it mattersFor a small-cap pharmaceutical player with a ₹23 Cr net worth, a successful fundraise can significantly accelerate expansion into complex formulations or increase manufacturing capacity, potentially scaling its ₹71 Cr TTM revenue base.
Board Meeting Date: August 8, 2026TTM Revenue: ₹71 CrNet Worth: ₹23 CrROCE: 30.0%Debt-to-Equity: 0.31Promoter Holding: 72.89%
📅 Short termThe stock may experience increased volatility and volume as the market anticipates the terms of the preferential allotment and the profile of the incoming investors.
📈 Long termIf the capital is deployed into high-margin pharmaceutical segments or capacity expansion, it could sustain the company's current growth trajectory and high return ratios.
⚠ Risk flags
- Equity dilution for existing retail shareholders
- Uncertainty regarding the specific end-use of funds
- Potential impact of API price volatility on margins
Key Highlights
Board meeting scheduled for August 8, 2026, to deliberate on fund raising via preferential allotment.
Trading window for designated persons closed from August 5, 2026, until 48 hours after the meeting outcome.
Company reported a significant revenue jump to ₹46.57 Cr in FY26 from ₹24.56 Cr in FY25.
Current TTM PAT stands at ₹8 Cr with an operating profit margin of 17.3%.
Promoter holding remains stable at 72.89% as of June 2026.
👀 What to Watch
Monitor the board meeting outcome on August 8 for the specific amount to be raised, the issue price, and the list of proposed allottees. This will clarify the extent of equity dilution and the strategic intent behind the capital infusion.
